Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Endometrial Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Rectal Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Cystadenocarcinoma, Serous 1Carcinoma in Situ 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Radiotherapy 10Cisplatin 9pembrolizumab 6Surveys and Questionnaires 6Methods 6Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 5fludarabine 4Papillomavirus Vaccines 4Early Intervention, Educational 4Cyclophosphamide 4Brachytherapy 4durvalumab 3aldesleukin 3Vaccines, Synthetic 3Vaccines 3Sentinel Lymph Node Biopsy 3Radiosurgery 3Radiation 3Platinum 3Palliative Care 3Paclitaxel 3Nivolumab 3Indocyanine Green 3Gemcitabine 3Drug Therapy 3Carboplatin 3Bleomycin 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3tremelimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × Diphenhydramine × Gynecologic × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡